Compare Centrus Energy Corp (LEU) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centrus Energy Corp vs Sana Biotechnology Inc — how do they compare? Centrus Energy Corp trades at $185.38 (market cap $3.77B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Centrus Energy Corp is far larger — about 3.3× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals.
| LEU | SANA | |
|---|---|---|
Market Cap | $3.77B | $1.13B |
Sector | Energy | Health |
52-Week High | $436.00 | $5.92 |
52-Week Low | $146.61 | $2.68 |
Enterprise Value | $3.08B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $185.06, down 2.26% on the day, with a bullish technical signal from moving averages and a neutral RSI near 61. The stock shows strong earnings beats in Q1 and Q2 2026 but missed in Q4 2025, with revenue growth to $474 million in 2026. Recent news highlights a $4.5 billion backlog and a $1 billion DOE contract for nuclear fuel supply, positioning the company in the expanding nuclear energy sector.
Outlook is positive due to government support and contract wins, but risks include margin compression and high valuation multiples. Analysts maintain a buy consensus with a $228.50 price target, suggesting 23% upside, though execution on production goals by 2029 is critical for sustained growth.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
